2023年第四季度及全年产品收入(DAXXIFY®和RHA®系列)分别为5850万美元和2.127亿美元,同比增长约28%和80%。
- 第四季度DAXXIFY销量比2023年第三季度增长22%,四分之三的第四季度收入来自重复订购账户。
- 2024年产品收入指导至少为2.8亿美...查看全文
Revance疗法(RVNC)03-20 06:45
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000066 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)03-20 06:55
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000068 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)03-22 04:15
$Revance疗法(RVNC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001479290-24-000072 Act: 34 Size: 1 MB 网页链接查看全文
Revance疗法(RVNC)03-09 05:35
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000056 Size: 5 KB 网页链接查看全文
Revance疗法(RVNC)05-03 20:55
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000088 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)02-29 07:06
$Revance疗法(RVNC)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001479290-24-000038 Act: 34 Size: 13 MB 网页链接查看全文
Revance疗法(RVNC)03-05 05:35
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000050 Size: 6 KB 网页链接查看全文
Revance疗法(RVNC)03-06 06:05
$Revance疗法(RVNC)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-059381 Act: 33 Size: 563 KB 网页链接查看全文
郑坚强2014-11-13 22:47
$Revance(RVNC)$ We are encouraged by the valuable and promising efficacy data observed among the patient and physician measurements, but the preliminary composite results were not adequate to move forward with our Phase 3 pivotal study at this time继续观望还不敢买查看全文
周朝先2014-11-13 22:37
$Revance(RVNC)$ @王半仙 @陈小邪要胜正
屌炸天!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!查看全文
$Revance疗法(RVNC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001479290-24-000100 Act: 34 Size: 7 MB 网页链接
$Revance疗法(RVNC)$ 8-K Current report, items 2.02, 7.01, 8.01, and 9.01 Accession Number: 0001479290-24-000099 Act: 34 Size: 362 KB 网页链接
$Revance疗法(RVNC)$ 8-K Current report, item 5.07 Accession Number: 0001479290-24-000092 Act: 34 Size: 150 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000086 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000088 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000087 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000089 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000090 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000085 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000084 Size: 7 KB 网页链接